Market capitalization | CHF2.17b |
Enterprise Value | CHF-311.46m |
PER (TTM) P/E ratio | 7.04 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -41.47 |
P/S ratio (TTM) P/S ratio | 288.47 |
P/B ratio (TTM) P/B ratio | 0.88 |
Dividend yield | 5.06% |
Last dividend (FY23) | CHF2.00 |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
1 Analyst has issued a forecast BB Biotech:
1 Analyst has issued a forecast BB Biotech:
Dec '23 |
+/-
%
|
||
Net profit | -207 -207 |
42%
42%
|
|
Depreciation and amortization | - - |
-
|
|
Share compensation | - - |
-
|
|
Operating cash flow | 212 212 |
7%
7%
|
|
Investments | - - |
-
|
|
Dividend paid | 156 156 |
26%
26%
|
|
Free cash flow | 212 212 |
7%
7%
|
Figures in millions CHF.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
BB Biotech AG is a closed-end investment fund, which engages in investing in biotechnology companies. It focuses on the development and commercialization of novel drugs sectors. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.
Head office | Switzerland |
Founded | 1993 |
Website | www.bbbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.